Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib . A non-comparative phase II multicenter study by the Scandinavian Sarcoma Group.
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms PAGIST
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 02 May 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016.
- 28 May 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2014 to 1 Sep 2015.